Clinical trials have demonstrated that semaglutide can reduce hemoglobin A1c by approximately 1.0-1.5% in patients with type 2 diabetes (with effects varying by dose and population) and produce weight loss of 10-15% of body weight when used at higher doses for obesity management
It aids in transporting fatty acids into mitochondria for energy production
An early meta-analysis suggested that 3 g/day may be necessary to normalize serum ALT in a significant patient proportion ( at 900 mg/day improved AST, ALT, and HbA1c in diabetic NAFLD patients
The publisher does not accept responsibility for errors, omissions, or outcomes
Phung, N., et al., Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis
To confirm this, we treated HUVECs with the proteasome inhibitor MG132 and the protein synthesis inhibitor cycloheximide (CHX, 10 g/mL)